Breaking News Instant updates and real-time market news.

CELG

Celgene

$93.93

0.82 (0.88%)

, XLRN

Acceleron

$41.19

0.62 (1.53%)

07:36
04/26/19
04/26
07:36
04/26/19
07:36

Celgene, Acceleron announces submission of luspatercept MAA to EMA

Celgene Corporation (CELG) and Acceleron Pharma (XLRN) announced that Celgene has submitted a Marketing Authorization Application to the European Medicines Agency for luspatercept for the treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes-associated anemia who have ring sideroblasts, require red blood cell transfusions and have received or are not eligible for erythropoiesis-stimulating agents, and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions. Luspatercept is an investigational erythroid maturation agent that regulates late-stage red blood cell maturation. The safety and efficacy results provided in the application are from the pivotal phase 3 studies MEDALIST and BELIEVE, evaluating the ability of luspatercept to effectively address anemia associated with MDS and beta-thalassemia, respectively. Luspatercept is an investigational therapy that is not approved for any use in any country.

CELG

Celgene

$93.93

0.82 (0.88%)

XLRN

Acceleron

$41.19

0.62 (1.53%)

  • 29

    Apr

  • 04

    May

  • 07

    May

  • 18

    May

  • 31

    May

  • 27

    Jun

  • 03

    Sep

CELG Celgene
$93.93

0.82 (0.88%)

04/01/19
BERN
04/01/19
DOWNGRADE
BERN
Market Perform
Celgene downgraded to Market Perform from Outperform at Bernstein
04/02/19
BERN
04/02/19
DOWNGRADE
BERN
Market Perform
Celgene downgraded to Market Perform from Outperform at Bernstein
Bernstein analyst Aaron Gal downgraded Celgene (CELG) to Market Perform from Outperform as spread narrows. The analyst notes that the current controversy on Celgene is whether the Bristol-Myers (BMY) acquisition will close. With limited upside, no differentiated views on the main controversy, and ahead of the shareholder vote on April 12th, the analyst is moving to the sidelines.
04/05/19
CANT
04/05/19
DOWNGRADE
CANT
Neutral
Celgene downgraded to Neutral from Overweight at Cantor Fitzgerald
04/05/19
CANT
04/05/19
DOWNGRADE
Target $100
CANT
Neutral
Cantor sees Bristol deal closing, downgrades Celgene to Neutral
Cantor Fitzgerald analyst Alethia Young downgraded Celgene (CELG) to Neutral from Overweight with an unchanged price target of $100. The analyst expects the takeover by Bristol-Myers (BMY) to close.
XLRN Acceleron
$41.19

0.62 (1.53%)

03/06/19
PIPR
03/06/19
NO CHANGE
PIPR
Departure of Gottlieb brings some biopharma uncertainty, says Piper Jaffray
Piper Jaffray remains "largely bullish" on the biopharma sector but acknowledges a "new and unexpected" source of uncertainty now with the announced departure of FDA commissioner Scott Gottlieb, analysts led by Christopher Raymond tell investors in a research note. With a track record of favoring innovation and pushing for increased regulatory efficiency while also advocating for more competition, Dr. Gottlieb was about as "market friendly, patient focused and industry friendly as one could have hoped," Piper writes. The firm adds that while it has no reason to believe the next commissioner "will be quite as radical and potentially damaging to the industry," it does think investors would do well to watch the selection process very closely.
04/04/19
PIPR
04/04/19
NO CHANGE
Target $74
PIPR
Overweight
Acceleron ACE-2494 program was 'high-risk', says Piper Jaffray
Piper Jaffray analyst Danielle Brill keeps her Overweight rating and $74 price target on Acceleron after its discontinued Phase 1 safety trial of ACE-2494. The analyst says the program was already seen as " high-risk due to several failures with similar approaches" and it was not included in her valuation. The analyst keeps a positive view on the stock, expecting the company's Phase 2 myelofibrosis data to drive shares higher in the second half of 2019.
04/05/19
HCWC
04/05/19
NO CHANGE
Target $66
HCWC
Buy
Acceleron's luspatercept has blockbuster potential, says H.C. Wainwright
After Acceleron (XLRN) and partner Celgene (CELG) announced their submission of a Biologics License Application for luspatercept in patients with myelodysplastic syndromes, or MDS, and also for patients with beta-thalassemia associated anemia, H.C. Wainwright analyst Edward White said he believes the product candidate is a "potential blockbuster." Acceleron and Celgene have said that peak luspatercept sales are expected to be over $2B, which implies $400M in expected royalties for Acceleron, noted White, who estimates luspatercept sales will top $1.3B in 2026. He keeps a Buy rating and $66 price target on Acceleron.
04/22/19
OPCO
04/22/19
UPGRADE
Target $59
OPCO
Outperform
Acceleron assumed with an Outperform from Perform at Oppenheimer
Oppenheimer analyst Leland Gershell assumed coverage of Acceleron Pharma and upgraded the shares to Outperform from Perform with a $59 price target. The company is "on the cusp" of generating revenue from product sales as well as entering a period of key pipeline newsflow, Gershell tells investors in a research note. Further, the analyst expects U.S. and European approval next year of luspatercept for anemia in two "significant" unmet medical needs, myelodysplastic syndromes and N2-thalassemia. Gershell views Acceleron's $2B peak sales guidance for the drug as conservative.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.